This observation is further supported by preclinical studies of breast cancer by Liu et al., who showed that administration of neoadjuvant nivolumab resulted in persistent expansion of CD8+ T cells even 170 days following infusion, which was not seen to the same magnitude following adjuvant administration of nivolumab26. The gene discussed is CD8A; the disease is breast cancer.